SNY
SanofiPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 16 ▼ UBS downgrades
- Jul 31 to Jul 31 3 court rulings: Pfizer Inc. v. Sanofi Pasteur Inc.; Pfizer Inc. v. Sanofi Vaccines US Inc. and 1 more
- Aug 14 ▲ Short interest falls 28.2% to 7.32M
- Aug 31 Hollingsworth v. Sanofi-Aventis US LLC et al
- Sep 7 Commission approves €400 million German State aid to…
- Sep 8 Trial readout: Results Pending: Fitusiran (Phase 3), Completed 35d ago
- Sep 18 Trial readout: Results Pending: Itepekimab (SAR440340) (Phase 3), Complet…
- Sep 30 Trial readout: Results Pending: Fitusiran (Phase 3), Completed 16d ago
- Oct 12 Trial readout: Results Pending: Fitusiran (Phase 3), Completed 69d ago
- Oct 13 to Oct 14 2 EU competition actions: Commission accepts commitments by Sanofi to address…; Opening remarks by Executive Vice-President Teresa Ribera…
- Oct 18 Trial readout: Results Pending: Itepekimab (SAR440340) (Phase 3), Complet…
- Oct 30 ▲ Sanofi reported Q3 2026 net sales of €14,444M (+14.3% CER) and busin…
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q3 2026: 33 added (1 new), 21 trimmed or exited.
- Short sellersSTEADY
Short interest +5.8% to 12.29M shares. 2.9 days to cover, ≈0.5% of shares.
- TrendUPTREND
13% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| DODGE & COX | TRIM | $646.0M |
| MORGAN STANLEY | ADD | $614.3M |
| FEDERATED HERMES, INC. | ADD | $224.9M |
| Qube Research & Technologies Ltd | DOUBLED | $89.3M |
| BARCLAYS PLC | TRIM | $64.9M |
| BANK OF MONTREAL /CAN/ | DOUBLED | $52.6M |
| Grantham, Mayo, Van Otterloo & Co. LLC | ADD | $17.0M |
| Cullen Capital Management, LLC | TRIM | $16.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jan 2026Price is inside the target range. Median implies +15%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jan 16, 2026 | UBS DOWNGRADE | Neutral |
| Jan 6, 2026 | Barclays DOWNGRADE | Equal-Weight |
| Dec 9, 2025 | Guggenheim DOWNGRADE | Neutral |
| Dec 8, 2025 | JP Morgan DOWNGRADE | Neutral |
| Sep 8, 2025 | Morgan Stanley UPGRADE | Overweight |
| Sep 2, 2025 | Deutsche Bank UPGRADE | Buy |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 5 bullish · 1 bearish · 2 mixed · 7 neutral- NEUTRAL INST-CLUSTERNov 4, 2026
Three asset managers increased Sanofi holdings by $5.7M in Q3 2026, led by Pzena more than…
The cluster is small and mixed, with no insider corroboration. Monitor upcoming earnings for any fundamental catalyst that might explain the modest accumulation by Pzena and Dimensional.
- BULLISH 6-KOct 30, 2026
Sanofi reported Q3 2026 net sales of €14,444M (+14.3% CER) and business EPS of €3.55 (+19.6% CER)…
The upgraded FY 2026 guidance (low-teens sales growth, mid-teens EPS growth at CER) signals sustained momentum into Q4. Watch for Q4 vaccine catch-up (influenza phasing) and the Regeneron…
- NEUTRAL SC 13G/AOct 26, 2026
Amundi filed an amended Schedule 13G disclosing a 5.70% passive stake in Sanofi as of September…
The modest increase from 5.50% to 5.70% is consistent with passive portfolio rebalancing. No further action warranted unless Amundi converts to a 13D filing, which would signal a shift to activist…
- NEUTRAL 6-KOct 26, 2026
Sanofi broke ground on a new insulin manufacturing facility in Frankfurt, Germany, with full…
Monitor Sanofi's future filings for capital expenditure details and any updates on the facility's licensing timeline. The investment signals long-term commitment to insulin manufacturing but has no…
All SNY filing & press-release reports (15)
- INST-CLUSTER reportNov 4, 2026
- 6-K reportOct 30, 2026
- SC 13G/A reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 1, 2026
- 6-K reportSep 17, 2026
- COURT-RULING reportAug 31, 2026
- COURT-RULING reportAug 17, 2026
- COURT-RULING reportAug 12, 2026
- COURT-RULING reportJul 31, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 27, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 7, 2026
- COURT-RULING reportApr 13, 2026